 | Up a level |
Number of items: 1.
Hakenberg, Oliver W., Perez-Gracia, Jose Luis 
ORCID: 0000-0003-4941-9075, Castellano, Daniel, Demkow, Tomasz, Ali, Tarek, Caffo, Orazio, Heidenreich, Axel, Schultze-Seemann, Wolfgang, Sautois, Brieuc, Pavlik, Ivan, Qin, Amy, Novosiadly, Ruslan D., Shahir, Ashwin, Ilaria, Robert, Jr. and Nippgen, Johannes
(2019).
Randomised phase II study of second-line olaratumab with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer.
Eur. J. Cancer, 107.
S. 186 - 196.
OXFORD:
ELSEVIER SCI LTD.
ISSN 1879-0852